# Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

> **NCT06733675** · PHASE1 · RECRUITING · sponsor: **Basilea Pharmaceutica** · enrollment: 46 (estimated)

## Conditions studied

- Healthy Volunteer
- Pharmacokinetics
- Safety
- Drug-Drug Interaction (DDI)
- FDC

## Interventions

- **DRUG:** Ledaborbactam etzadroxil
- **DRUG:** Ceftibuten
- **DRUG:** Ceftibuten-ledaborbactam etzadroxil
- **DRUG:** Esomeprazole

## Key facts

- **NCT ID:** NCT06733675
- **Lead sponsor:** Basilea Pharmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-07
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06733675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06733675, "Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06733675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*